Acalabrutinib — Drug Intelligence | 37 EU Trials

Filter these 37 trials by condition, phase, country and more.

Open in Search →

37 Registered trials

15 Recruiting

19 Completed trials

19 Sponsors

22 Countries

Phase III

Phase II

Phase I/II

Phase III: 16 Phase II/III: 1 Phase II: 14 Phase I/II: 5 Phase IV: 1

Indications tested

Diffuse large B-cell lymphoma 3 Chronic lymphocytic leukaemia 3 High grade B-cell lymphoma Burkitt-like lymphoma 1 Marginal zone lymphoma 1 Waldenstrom's macroglobulinaemia refractory 1 B-cell lymphoma recurrent 1 B-cell unclassifiable lymphoma high grade 1 Mantle cell lymphoma refractory 1 Waldenstrom's macroglobulinaemia recurrent 1 B-cell small lymphocytic lymphoma recurrent 1 Mantle cell lymphoma 1 Richter's syndrome 1

Sponsors using this IMP

Acerta Pharma B.V. 10 AstraZeneca AB 6 Ascentage Pharma Group Inc. 3 Merck Sharp & Dohme LLC 2 University Of Cologne 2 AbbVie Deutschland GmbH & Co. KG 1 Association International Extranodal Lymphoma Study Group (IELSG) 1 Astrazeneca Farmaceutica Spain S.A. 1 BeOne Medicines AG 1 BioInvent International AB 1 French Innovative Leukemia Organization 1 Haemato Oncology Foundation For Adults Netherlands 1

All trials — page 2

37 total

A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended

2023-509358-72-00 Phase III 9 countries Acerta Pharma B.V.
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma Ended

2023-509350-63-00 Phase I/II 1 country Acerta Pharma B.V.
This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre… Ended

2023-509349-11-00 Phase III 13 countries Acerta Pharma B.V.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi… Ended

2023-509354-58-00 Phase III 9 countries Acerta Pharma B.V.
A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisi… Ended

2023-509359-15-00 Phase III 4 countries Acerta Pharma B.V.
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High R… Ended

2023-509347-27-00 Phase III 2 countries Acerta Pharma B.V.
An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia1 Ended

2023-509356-34-00 Phase II 3 countries Acerta Pharma B.V.
A trial to see the effects of increased doses of ACP-196 (the test drug) in subjects with Leukemia Ended

2023-509346-35-00 Phase I/II 1 country Acerta Pharma B.V.
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi… Ended

2023-509348-84-00 Phase III 9 countries Acerta Pharma B.V.
CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended

2023-507002-14-00 Phase II 2 countries University Of Cologne
Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended

2023-507669-24-00 Phase III 9 countries Astrazeneca AB
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended

2023-506641-35-00 Phase II 4 countries Kite Pharma Inc.
A Trial to See the Effects of ACP-196 (the test drug) in Patients who have Mantle Cell Lymphoma Ended

2023-509352-34-00 Phase II 2 countries Acerta Pharma B.V.

Showing 25–37 of 37 trials

← All drugs A–Z